Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study
Philippe Judlin A , Anne-Carole Jacquard B J , Xavier Carcopino C D , François Aubin E F , André Dahlab B , Frédéric Mistretta G , Didier Not G , Pierre-Yves Boelle H , Olivier Aynaud I and Benoît Soubeyrand B
+ Author Affiliations
- Author Affiliations
A Pôle de Gynécologie, Obstétrique et Reproduction, Maternité régionale universitaire de Nancy, 10, rue du Dr Heydenreich – CS 74213-54 042 Nancy Cedex, France.
B Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon Cedex 07, France.
C Department of Obstetrics and Gynaecology, Assistance Publique des Hôpitaux de Marseille (APHM), Hôpital Nord, Chemin des Bourrely, 13915 Marseille cedex 20, France.
D Aix-Marseille Université (AMU), University of Medicine, 51, Boulevard Pierre Dramard 13916 Marseille cedex 20, France.
E EA3181, SFR FED 4234, Université de Franche-Comté, Bâtiment INSERM, 20 rue Françoise Dolto, 25000 Besançon, France.
F Dermatology Department, University Hospital, 3, boulevard Fleming, 25000 Besançon, France.
G RCTS, 38 Rue du Plat, 69002 Lyon, France.
H Faculté de Médecine Pierre et Marie Curie, INSERM UMR S707, APHP, 27, rue de Chaligny, 75571 Paris, Cedex 12, France.
I Dermatology Department, University Hospital Cochin, 89, rue d’Assas, 75006 Paris, France.
J Corresponding author. Email: ACJacquard@spmsd.com
Sexual Health 13(1) 49-54 https://doi.org/10.1071/SH14218
Submitted: 11 November 2014 Accepted: 8 September 2015 Published: 16 November 2015
Abstract
Background: The objective was to evaluate the effect of a HPV vaccination program on the incidence proportion of a proxy, genital warts (GW), in women in France. Methods: The number of primary GW cases was prospectively recorded over two 4-month periods before (T0: Dec 2008 to March 2009) and after (T1: Dec 2011 to March 2012) a HPV vaccination program. A total of 160 gynaecologists participated in T0 and 189 in T1. Primary genital herpes (HSV) infection was used as a control. Results: During T0, 39 190 15- to 26 year-old women were seen, of whom 176 were diagnosed with GW (incidence proportion: 0.45%) and 155 with primary HSV infection (incidence proportion: 0.39%). During T1, 45 628 females were seen [229 with GW (incidence proportion: 0.50%) and 202 with HSV (incidence proportion: 0.44%)]. In the 15–20 years age category, the incidence proportion of primary GW decreased from 0.41% to 0.30% (P = 0.128) between T0 and T1, and the proportion of women newly diagnosed with primary genital herpes diseases slightly increased from 0.34% to 0.38% (P = 0.620). In the 15–18 years age group, this decrease became significant (0.34% to 0.18%; P = 0.048). Conclusions: A trend for a non-significant decreased incidence proportion of GW was observed in young women below 20 years who are more frequently vaccinated. This may be the result of HPV vaccination and suggests that a substantial increase in vaccine coverage could lead to a more pronounced decreased incidence proportion of GW in the future.
Additional keywords: genital herpes, HPV vaccination, incidence proportion.
References
[1] Dayyani F, Etzel CJ, Liu M, Ho CH, et al Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2 15| Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).Crossref | GoogleScholarGoogle Scholar | 20587061PubMed |
[2] De Vuyst H, Clifford GM, Nascimento MC, et al Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124 1626–36.
| Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXivVars74%3D&md5=41a18a6aca463e0a7985cca42d8d880aCAS | 19115209PubMed |
[3] Mehanna H, Jones TM, Gregoire V, et al Oropharyngeal carcinoma related to human papillomavirus. BMJ Clin Res 2010; 340 c1439
[4] Miralles-Guri C, Bruni L, Cubilla AL, et al Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62 870–8.
| Human papillomavirus prevalence and type distribution in penile carcinoma.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1MnkvFKhuw%3D%3D&md5=767e2811354a70d5772750781a11654bCAS | 19706632PubMed |
[5] Brown DR, Schroeder JM, Bryan JT, et al Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37 3316–22.
| 1:STN:280:DyaK1MvhvFWlsg%3D%3D&md5=e4282499dfd359ee3fcff089340f5affCAS | 10488198PubMed |
[6] Potocnik M, Kocjan BJ, Seme K, et al Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia. Acta Dermatovenerol Alp Panmonica Adriat 2007; 16 91–6.
| 1:STN:280:DC%2BD2snns12ksA%3D%3D&md5=eccb8e1044c2781da178177130c3d389CAS |
[7] Monsonego J, Breugelmans JG, Bouee S, et al [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil 2007; 35 107–13. [in French].
| 1:STN:280:DC%2BD2s7ntVGgsQ%3D%3D&md5=8672899370ee44aff11428f7a4b9d692CAS | 17270482PubMed |
[8] Villa LL, Costa RL, Petta CA, et al Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6 271–8.
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.Crossref | GoogleScholarGoogle Scholar | 15863374PubMed |
[9] Haut Conseil de la Santé Publique 2013 vaccination schedule and recommendations from the “Haut Conseil de la santé publique” in France. BEH 2013; 14–15 129–58.
[10] Fagot JP, Boutrelle A, Ricordeau P, et al HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29 3610–6.
| HPV vaccination in France: uptake, costs and issues for the National Health Insurance.Crossref | GoogleScholarGoogle Scholar | 21382486PubMed |
[11] Fonteneau L, Guthmann JP, Lévy-Bruhl D. Estimation des couvertures vaccinales en France à partir de l’Échantillon généraliste des bénéficiaires (EGB): exemples de la rougeole, de l’hépatite B et de la vaccination HPV. BEH 2013; 8–9 72–6. [in French].
[12] Bertaut A, Chavanet P, Aho S, et al HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Cote d’Or. Eur J Obstet Gynecol Reprod Biol 2013; 170 526–32.
| HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Cote d’Or.Crossref | GoogleScholarGoogle Scholar | 23953913PubMed |
[13] Ganry O, Bernin-Mereau AS, Gignon M, et al Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors. Rev Epidemiol Sante Publique 2013; 61 447–54.
| Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3sbmsVKkug%3D%3D&md5=a06d1a3effa69fe5c7233d3feb04e8c1CAS | 24016739PubMed |
[14] Sabiani L, Bremond A, Mortier I, et al [HPV prophylactic vaccine coverage in France: results of a survey among high school and university students in Marseilles’ area]. J Gynecol Obstet Biol Reprod (Paris) 2012; 41 136–44.
| [HPV prophylactic vaccine coverage in France: results of a survey among high school and university students in Marseilles’ area].Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38zns1Cgsg%3D%3D&md5=12df49806eed6d9bad3ed51c5f93305fCAS | 22093439PubMed |
[15] Health Protection Agency. Trends in anogenital warts and anogenital herpes simplex virus infection in the United Kingdom: 1996 to 2005. CDR Weekly 2006; 16 (48): 1–4. Available online at: http://webarchive.nationalarchives.gov.uk/+/http://www.hpa.org.uk/cdr/archives/2006/cdr4806.pdf [verified January 2014].
[16] European Medicines Agency. Gardasil – summary of product characteristics (Updated November 2013). Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf [verified March 2014].
[17] Cassell JA, Mercer CH, Sutcliffe L, et al Trends in sexually transmitted infections in general practice 1990–2000: population based study using data from the UK general practice research database. BMJ Clin Res Ed 2006; 332 332–4.
| Trends in sexually transmitted infections in general practice 1990–2000: population based study using data from the UK general practice research database.Crossref | GoogleScholarGoogle Scholar |
[18] Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31 748–52.
| Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States.Crossref | GoogleScholarGoogle Scholar | 15608590PubMed |
[19] Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009; 85 111–5.
| Epidemiology and costs associated with genital warts in Canada.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1M3is1Crug%3D%3D&md5=c8dc0c2150a133d97ee5b2e6e53b37acCAS | 18981170PubMed |
[20] Veluire M, Brasnu D. Evolution of sexual behaviour in France and emergence of new head and neck cancers. Bull Cancer 2011; 98 1185–92. [in French].
| 22008184PubMed |
[21] Amate P, Luton D, Davitian C. Contraception and adolescence]. Arch Pediatr 2013; 20 707–13. [in French].
| Contraception and adolescence].Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3srpt1ynsQ%3D%3D&md5=a6cc62a389eb77d49e351b1bc1bfaaf5CAS | 23628120PubMed |
[22] Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103 1428–35.
| Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination.Crossref | GoogleScholarGoogle Scholar | 23763409PubMed |
[23] Markowitz LE, Hariri S, Lin C, et al Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013; 208 385–93.
| Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhtFSiu7zE&md5=1ad2f85d7c015abe4114d645353f5c6dCAS | 23785124PubMed |
[24] Hariri S, Markowitz LE, Dunne EF, et al Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013; 53 679–82.
| Population impact of HPV vaccines: summary of early evidence.Crossref | GoogleScholarGoogle Scholar | 24263069PubMed |
[25] Ali H, Donovan B, Wand H, et al Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ Clin Res 2013; 346 f2032
[26] Read TR, Hocking JS, Chen MY, et al The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87 544–7.
| The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.Crossref | GoogleScholarGoogle Scholar | 21970896PubMed |
[27] Baandrup L, Blomberg M, Dehlendorff C, et al Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40 130–5.
| 23324976PubMed |
[28] Leval A, Herweijer E, Arnheim-Dahlstrom L, et al Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206 860–6.
| Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.Crossref | GoogleScholarGoogle Scholar | 22815381PubMed |
[29] Mikolajczyk RT, Kraut AA, Horn J, et al Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013; 40 28–31.
| Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study.Crossref | GoogleScholarGoogle Scholar | 23250300PubMed |
[30] Brotherton JM, Deeks SL, Campbell-Lloyd S, et al Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell Q Rep 2008; 32 457–61.
| 19374275PubMed |
[31] Denis F, Levy-Bruhl D. Mass vaccination against hepatitis B: the French example. Curr Top Microbiol Immunol 2006; 304 115–29.
| Mass vaccination against hepatitis B: the French example.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD28rmtl2nsQ%3D%3D&md5=1851cbd5941e73c5e7d4bafdd0c02b3bCAS | 16989267PubMed |
